Picture EBD Group Biotech Showcase 2023 San Francisco 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4947 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 48 49 50  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
JnJ–Valneva: investment, 201502 acquisition €45m of Crucell Sweden AB + affiliates incl all assets related to Dukoral 2015-02-10
Signature Diagnostics–Roche: investment, 201502 acquisition of SDx by Roche 2015-02-09
Exquiron Biotech–SAMDI Tech: drug discovery services, 201502– collab mutually co-promotion of respective services in Europe + North America 2015-02-08
Advanced Scientifics–Thermo Fisher: investment, 201502 acquisition $300m in cash 2015-02-05
Nanion–Ratos: patch clamp technology, 201502– license non-excl to key patent providing freedom-to-operate for life time of patent from Biolin 2015-02-05
SciLifeLab (SE)–Fluidigm: CyTOF mass cytometer, 201502 supply three CyTOF 2 systems to Swedish National Center for Single-Cell Analysis 2015-02-05
Zedira–Germany (govt): grant, 201502– BMBF funding €1m to support further coagulation factor XIIIa inihibitor development 2015-02-03
Zedira–Univ Marburg: structural biology, 201502 collab existent w group of Prof Gerhard Klebe 2015-02-03
Poonawalla–Genticel: vaccine technology, 201502– license to Vaxiclase platform for pertussis vaccine $57m upfront + milestones + royalties to SII 2015-02-02
R2R Biofluidics project–EU (govt): grant, 201502–201901 H2020 grant €6.4m out of total budget of €7.9m 2015-02-01
Atlas Genetics–Bellevue: investment, 201501 financing round Series C totalling $20m incl returning investor BB Biotech Ventures 2015-01-29
Atlas Genetics–Novartis: investment, 201501 financing round Series C totalling $20m incl returning investor Novartis Venture Funds 2015-01-29
Atlas Genetics–Russia (govt): investment, 201501 financing round Series C totalling $20m incl new investor RMI Partners 2015-01-29
Atlas Genetics–SEVERAL: investment, 201501 financing round Series C $20m from existing investors + new investor RMI Partners 2015-01-29
Nanocomp–Evonik: investment, 201501– strategic minority investment €na by Evonik Venture Capital 2015-01-29
Oncgnostics–High-Tech Gründerfonds: investment, 201501 financing round Series A totalling € 7-digit incl existing investor HTGF 2015-01-29
Oncgnostics–SEVERAL: investment, 201501 financing round Series A € 7-digit led by new investor bm|t 2015-01-29
Fodjan–High-Tech Gründerfonds: investment, 201501 seed investment € 6-digit by HTGF 2015-01-28
Ratos–Xention: patch clamp technology, 201501 acquisition key patent by Biolin Scientifc from Xention Ltd 2015-01-27
Dacheng–Dentons: investment, 201501– merger signed to become largest law firm ww 2015-01-26
Nanion–Tokyo Women’s Medical Univ: patch clamp system, 201501– collab optimising performance of iPS cells an Nanion systems 2015-01-22
Sigma-Aldrich–VIB: research reagents, 201501– alliance to provide products + tools + technologies for translational research 2015-01-22
BioNova Cientifica–Genetrix (ES): nucleic acid amplification technology, 201501– distribution of Sygnis TruePrime Single Cell WGA kit in Spain 2015-01-21
InnoCyte–PharmaCell: cell analysis technology, 201501– collab within Biomat-IN network to scientifically support cell passage device 2015-01-21
Trophos–Roche: investment, 201501 acquisition €120m upfront cash + €350m milestones 2015-01-16
ASPEC Technologies–CovalX: mass spectrometry, 201501 collab existent ASPEC is distributor of CovalX High-Mass systems in China 2015-01-15
Sanofi–Boehringer: biologics contract manufacturing, 201501– supply strategic manufacturing alliance to supply therapeutic ABs to Sanofi 2015-01-15
Roche–Human Longevity: genome sequencing services, 201501– supply €na multi-year agreem with Genentech for whole genome sequencing + data analysis 2015-01-14
Boehringer–Vanderbilt Univ: Ras inhibitors, 201501– collab multi-year €na RnD small-molecule Ras inhibitors for cancer 2015-01-13
Boehringer–Vanderbilt Univ: Ras inhibitors, 201703– collab expansion RnD small-molecule KRAS inhibitors for cancer 2015-01-13
Boehringer–Yale Univ: immunotherapy, 201501– collab identification of targets + agents w excl licensing option for BI 2015-01-13
Cortendo–SEVERAL: investment, 201501 private placement $27.5m (SEK221m) incl RA Capital + NEA + Broadfin Capital + HealthCap 2015-01-13
GenePOC–Debiopharm: investment, 201501 financing round led by Debiopharm Diagnostics + Emerillon Capital 2015-01-13
GenePOC–SEVERAL: investment, 201501 financing round led by Debiopharm Diagnostics + Emerillon Capital 2015-01-13
Artel–Stratec: liquid handling technology, 201501– distribution excl marketing of Tholos liquid handling quality assurance instrumentation solution 2015-01-12
Foundation Medicine–Roche: investment, 201501– acquisition majority share up to 56.3% via $780m tender offer + $250m new shares $50/share 2015-01-12
JnJ–AC Immune: therapeutic vaccines, 201501– collab + license up to $509m (CHF500m) ACI-35 + 3y research therap vaccines for tauopathies 2015-01-12
Valneva–SEVERAL: investment, 201501–201502 capital increase €45m 18.23m new ordinary shares to finance acquisition of Crucell Sweden AB 2015-01-12
Qiagen–ArcherDX: DNA sequencing technology, 201501– distribution €na of Archer NGS products by Qiagen 2015-01-11
Agenus–Incyte: investment, 201501 equity investment $35m at $4.51/share by Incyte as part of ww cancer immunotherapy alliance 2015-01-09
Incyte–Agenus: cancer immunotherapy, 201501– collab ww alliance $25m upfront + $350m milestones + $35m equity investment using Retrocyte Display techn 2015-01-09
Haplogen–Horizon Discovery: investment, 201501 acquisition of Haplogen Genomics GmbH for upfront €3.8m cash + €3.8m shares + €5m milestones in shares 2015-01-08
Miracor–SEVERAL: investment, 201501 financing round Series B extension €4.5m from BioMedInvest + AWS + SHS + Earlybird + Delta Partners 2015-01-08
Addex–United States (govt): ADX71441, 201501– collab NIAAA to evaluate ADX71441 in preclinical models of alcohol use disorder 2015-01-07
Affimed–Germany (govt): grant, 201501– BMBF grant €2.4m to develop Trispecfic ABs within KMUinnovative BioChance program 2015-01-07
Affimed–MacDougall Biomedical Communications: public relations, 201501 service existent by MacDougall Munich Office 2015-01-07
Caribou Biosciences–Novartis: investment, 201501 equity investment by Novartis in connection w collab + license agreement 2015-01-07
Close Brothers–Oddo: investment, 201501 acquisition of Close Brothers Seydler Bank AG by Oddo & Cie 2015-01-07
Genkyotex–SEVERAL: investment, 201501 financing round Series D CHF20m=$21m led by new investor NeoMed Management 2015-01-07
Intellia Therapeutics–Novartis: investment, 201501 increase of equity investment by Novartis 2015-01-07
Novartis–Caribou Biosciences: CRISPR technology, 201501– collab + license agreem non-excl for devlopm of drug discovery tools 2015-01-07
Novartis–Intellia Therapeutics: CRISPR technology, 201501– collab + license agreem incl upfront paym + investm + funding + milestones + royalties 2015-01-07
Gilead–Phenex: FXR agonists, 201501 acquisition of Phenex’ FXR agonists program for NASH + other liver diseases for up to $470m 2015-01-06
OnCore BioPharma–Cytos Biotechnology: VLP technology, 201501– license to OnCore excl for use of VLP platform in treatm + prevention of HBV infections 2015-01-06
Provendis–TVM: venture capital, 201501– collab support in project evaluation + financing by TVM Capital Life Science for projects of Provendis 2015-01-06
Boehringer–BioMed X: pharma research, 201501– collab new BioMed X research group to discover new epigenetic COPD regulators 2015-01-05
Redbiotec–Pfizer: investment, 201501 acquisition of controlling interest in Redvax GmbH, a spin-off from Redbiotec AG 2015-01-05
Aevotis–Evocatal: investment, 201501 acquisition €na of majority stake by Evocatal 2015-01-01
Aquila Biolabs–SEVERAL: investment, 2015 seed financing round 7-digit € 2015-01-01
Atomwise–SEVERAL: investment, 2015 seed financing round incl Y Combinator + Khosla Ventures + DJF 2015-01-01
Bayer–Proteros: drug discovery services, 201501–201612 collab identification of cardiovascular compounds for integral membrane protein 2015-01-01
Biocentric–Hain Lifescience: investment, 2015 acquisition of Biocentric by Hain 2015-01-01
EffRx–SEVERAL: investment, 201501 financing round CHF2.3m from existing investors 2015-01-01
GreenBone–SEVERAL: investment, 2015 seed financing round €3m from ZernikeMeta Ventures + Italian Angels for Growth + private investors 2015-01-01
IFM Therapeutics–Atlas Venture: investment, 2015 seed funding by Atlas Venture 2015-01-01
Jecure Therapeutics–Versant Ventures: investment, 2015 seed financing from founding investor Versant Ventures 2015-01-01
KBI BioPharma–JSR Corp: investment, 2015 acquisition of KBI BioPharma Inc by JSR Corp 2015-01-01
Kurma–SEVERAL: investment, 2015 final closing €35m of Kurma Diagnostics Fund (KDx) 2015-01-01
Mérieux–Copan: sample prep automation, 201501– collab distribution of WASP + WASPLab systems by bioMérieux starting in FR+DE+UK + to be expanded 2015-01-01
Novartis–Fraunhofer: cell therapy production, 201501– collab developm of production capacity for Kymriah in Europe at Fraunhofer IZI 2015-01-01
Novartis–Fraunhofer: cell therapy production, 201808– service supply production of Kymriah in Europe by Fraunhofer IZI 2015-01-01
Numares–SHS Capital: investment, 2015 existent SHS Gesellschaft für Beteiligungsmanagement is main shareholder 2015-01-01
Oncgnostics–MDxHealth: PCR technology, 201501– license ww non-excl for MSP technology for cervical cancer diagnostics to Oncgnostics 2015-01-01
Padlock Therapeutics–Evotec: drug discovery services, 201501–201703 extension of collab to deliver multiple PAD inhibitor development candidates 2015-01-01
Proteomedix–SEVERAL: investment, 201501 2nd closing of financing round Series B CHF1m bringing total round to CHF4.2m 2015-01-01
Roche–4D Molecular Therapeutics: gene delivery technology, 2015– collab research 2015-01-01
Seres Therapeutics–Nestlé: investment, 201501 equity investment by Nestlé Health Science 2015-01-01
VIB–Lipotype: mass spectrometry services, 2015– collab supply of shotgun lipidomics services by Lipotype to researchers at VIB 2015-01-01
ViraTherapeutics–Austria (govt): investment, 2015c financing €1.6m from FFG + aws seed financing programme 2015-01-01
Enzymatics–Qiagen: investment, 201412 acquisition €na of all assets of Enzyme Solution Unit of Enzymatics by Qiagen 2014-12-31
RiNA GmbH–NONE: investment, 201412–201506 bankruptcy AG Berlin-Charlottenburg 36R IN 4968/14 Massenunzulänglichkeit 2014-12-29
Pieris–Trout Group: public relations, 201412 service existent 2014-12-23
Bruker–Univ Alberta: mass spectra database, –201412 collab development of Bruker HMDB Metabolite Library 2014-12-19
Pieris–Ally Bridge Group: investment, 201412 private placement totalling $13.56m incl investor ABG 2014-12-18
Annexon–Clarus Ventures: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Clarus Ventures 2014-12-15
Annexon–Novartis: investment, 201412 financing round Series A-1 totaliing $34m incl lead investor NVF 2014-12-15
Annexon–Satter Investment Management: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Satter 2014-12-15
Annexon–SEVERAL: investment, 201412 financing round Series A-1 $34m led by NVF + incl Satter Investment + Clarus Ventures 2014-12-15
Takasago–Evolva: fermentation technology, 201412– collab developm production technology for flavours + fragrances 2014-12-11
Bayer–Orion Corp: cancer drug, 201412 existent collab ww developm + marketing of oral androgen receptor modulator ODM-201 for prostate cancer 2014-12-02
Nanolive–SEVERAL: investment, 201412 closing of 1st financing round 2014-12-01
Tiziana–Novimmune: therapeutic antibody, 201412– license to foralumab (NI-0401) to Tiziana 2014-12-01
Pepperprint–Sciomics: microarray technology, 201411– collab distribution + marketing for antibody characterisation + biomarker discovery 2014-11-18
Covance–LabCorp: investment, 201411–201502 acquisition $6.2b w $107.19/share paid $75.76 in cash + 0.26886 LabCorp shares per Covance share 2014-11-02
Weizmann Institute–XL-protein: PASylation technology, 201410– Yeda acquires ww excl marketing + outlicensing rights to PAS-YNSa8 dev by XL + Weizmann 2014-10-21
Epigenomics–BioChain: investment, 201410 acquisition €4.2m 1.35m new shares €3.08/share by BioChain Institute Inc 2014-10-16
Roche–NewLink Genetics: cancer drugs, 201410– collab drug discovery IDO/TDO inhibitors with Genentech 2014-10-16
Roche–AbVitro: PETE technology, 201410 acquisition €na of primer extension based target enrichment technology by Roche 2014-10-09
Mimetas–SEVERAL: investment, 201510 financing round $5.2m from ZIF + PPM Oost et al 2014-10-08
Abionic–SEVERAL: investment, 201410 financing round Series B CHF3.8m 2014-10-01
next pagenext page 1 2 3 ... 48 49 50  next pagenext page


Picture [iito] Männer Ballett 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Campus Berlin-Buch GmbH BBC BerlinBioCube Start-up Center 650x300px

» top